PAU15 Antibody

What is PAU15 and what is its biological significance in yeast?

PAU15 (encoded by gene PAU15) is a member of the seripauperin protein family found in Saccharomyces cerevisiae (Baker's yeast), specifically in the strain ATCC 204508/S288c . The protein is identified in the UniProt database with the accession number P40585 . The seripauperin family consists of approximately 20 members that are thought to play roles in cell wall structure and stress response in yeast.

Unlike better-characterized proteins like PEA-15 (which shows expression in mammalian tissues including the brain and is detectable via specific antibodies in neurons and cortex tissue) , PAU15's exact biological functions remain less extensively documented. The protein appears to be part of the cellular response mechanisms that help yeast adapt to environmental stressors, similar to how other specialized proteins function in different organisms.

What detection methods are most effective when working with PAU15 antibody?

Based on established practices with similar yeast protein antibodies, Western blotting represents one of the most reliable detection methods for PAU15. When optimizing detection protocols:

• Sample preparation should include proper cell lysis under conditions that preserve protein integrity

• Protein separation should be performed on SDS-PAGE gels with appropriate percentage (typically 12-15% for lower molecular weight yeast proteins)

• Transfer conditions must be optimized for smaller proteins

• Blocking solutions should be carefully selected to minimize background without compromising specific binding

For immunohistochemistry applications, researchers should consider fixation techniques compatible with yeast cell wall structures. Drawing from practices with other antibodies like those against PEA-15, immersion-fixed paraffin-embedded sections can be effective when using appropriate antigen retrieval methods .

How should researchers validate PAU15 antibody specificity in yeast models?

Validation of PAU15 antibody specificity requires multiple complementary approaches:

• Genetic controls: Testing the antibody in wild-type vs. PAU15 knockout strains represents the gold standard validation approach. Absence of signal in knockout strains strongly confirms specificity.

• Peptide competition assays: Pre-incubation of the antibody with excess recombinant PAU15 protein should abolish specific binding in subsequent detection applications.

• Cross-validation using multiple antibodies: When available, using multiple antibodies targeting different epitopes of PAU15 can provide stronger evidence of specificity.

• Molecular weight confirmation: Ensuring the detected band corresponds to the expected molecular weight of PAU15.

These validation approaches align with standard practices seen in the validation of other research antibodies such as those against PEA-15, where specific bands at expected molecular weights (approximately 15 kDa in the case of PEA-15) confirm proper detection .

What experimental considerations are critical when using PAU15 antibody for stress response studies?

When investigating stress responses in yeast using PAU15 antibody, researchers should implement the following experimental design elements:

• Appropriate stress induction protocols: Standardize the application of stressors (osmotic, oxidative, temperature) to ensure reproducibility.

• Time-course analyses: PAU family gene expression typically follows specific temporal patterns during stress. Design experiments to capture both early (0-30 minutes) and late (1-24 hours) responses.

• Strain selection considerations: Different yeast strains may express varying levels of PAU15. The antibody has been validated with Saccharomyces cerevisiae strain ATCC 204508/S288c specifically .

• Quantification methods: Implement digital image analysis for Western blots to accurately quantify changes in expression levels.

• Control proteins: Include detection of constitutively expressed proteins that remain stable during stress responses as loading controls.

This approach parallels methods used in studying stress-responsive proteins in other contexts, such as the investigation of PED/PEA-15 expression patterns in relation to regulatory factors like HNF4 alpha in human cell studies .

How can researchers optimize immunoprecipitation protocols with PAU15 antibody?

Optimizing immunoprecipitation (IP) protocols for PAU15 requires addressing several technical challenges specific to yeast proteins:

• Cell lysis optimization: Yeast cells require specialized lysis buffers and mechanical disruption methods. Consider using glass bead disruption or enzymatic treatment with zymolyase followed by gentle detergent lysis.

• Antibody coupling strategies:

  • Direct coupling to beads using chemical crosslinking

  • Pre-formation of antibody-protein complexes followed by capture with Protein A/G

  • Sequential IP approaches for detecting interaction partners

• Buffer composition considerations:

  Buffer Component	Recommended Range	Purpose
  NaCl	100-150 mM	Maintain protein-protein interactions
  Detergent	0.1-0.5% NP-40 or Triton X-100	Solubilize membranes without disrupting complexes
  Protease inhibitors	1X complete cocktail	Prevent degradation during processing
  Phosphatase inhibitors	1X cocktail	Preserve phosphorylation states if studying PTMs
  pH	7.2-7.4	Maintain native protein conformations

• Elution strategies: Consider both harsh (boiling in sample buffer) and gentle (peptide competition) elution methods depending on the downstream application.

These approaches draw from successful IP protocols developed for other antibodies that have demonstrated utility in isolating protein complexes, as described for PED/PEA-15 antibodies that have been validated for immunoprecipitation applications .

What approaches should be used to analyze PAU15 post-translational modifications?

Analysis of post-translational modifications (PTMs) of PAU15 requires specialized techniques:

• Phosphorylation site mapping:

  • Use phospho-specific antibodies if available

  • Implement mass spectrometry analysis following IP

  • Consider comparing PTM patterns under different stress conditions

• Other potential PTMs to investigate:

  • Ubiquitination status (critical for protein turnover)

  • Glycosylation patterns (may affect localization)

  • SUMOylation (often affects protein interactions)

• Analytical workflow for PTM characterization:
  a. Enrich for PAU15 using optimized IP protocol
  b. Separate proteins using 2D gel electrophoresis to resolve modified forms
  c. Perform mass spectrometry analysis on isolated spots
  d. Validate findings using specific PTM inhibitors in vivo

This methodological approach parallels techniques used for analyzing phosphorylation status of related proteins, such as the study of phosphorylated PED at specific sites (PED S116 and PED S104) in comparison to total PED protein in research contexts .

How can researchers address cross-reactivity issues with PAU15 antibody?

The PAU gene family in yeast consists of multiple members with high sequence homology, creating potential cross-reactivity challenges. To address these issues:

• Epitope analysis: Determine which region of PAU15 the antibody targets and compare sequence homology with other PAU family members.

• Absorption protocol: Pre-absorb antibody with recombinant proteins from related PAU family members to deplete cross-reactive antibodies.

• Validation in deletion strains: Test antibody specificity in strains where individual PAU genes have been deleted.

• Western blot optimization: Increase washing stringency and optimize blocking conditions to reduce non-specific binding.

• Epitope mapping: Consider using epitope mapping to identify the exact binding region of the antibody.

This approach is consistent with cross-reactivity assessment methods used for other antibody types, such as tissue cross-reactivity studies performed for therapeutic monoclonal antibodies like PBP1510, which demonstrated specific binding to target tissues without significant non-specific interactions .

What considerations are important when comparing data from different PAU15 antibody preparations?

When comparing results obtained using different PAU15 antibody preparations (polyclonal vs. monoclonal, different sources, or different lots), researchers should:

• Document key antibody characteristics:

  Parameter	Documentation Needed
  Antibody type	Polyclonal vs. monoclonal origin
  Immunogen	Exact sequence/region used for immunization
  Host species	Rabbit, mouse, etc.
  Affinity	Quantitative binding kinetics if available
  Validation methods	Tests performed to confirm specificity
  Optimal working dilutions	For each application (WB, IF, IP)

• Perform side-by-side comparisons: When transitioning between antibody preparations, run parallel experiments to establish correlation factors.

• Maintain antibody validation records: Create detailed documentation of validation experiments for each new antibody lot.

• Consider epitope differences: Different antibodies may recognize distinct epitopes that could be differentially accessible under various experimental conditions.

This methodical approach to antibody characterization aligns with practices used in the development of high-affinity monoclonal antibodies, where detailed documentation of specificity, affinity, and application suitability is standard practice .

How can PAU15 antibody be used to investigate protein-protein interactions in stress response pathways?

Investigating protein-protein interactions involving PAU15 requires sophisticated approaches:

• Co-immunoprecipitation strategies:

  • Forward and reverse co-IP approaches to confirm interactions

  • Stepwise buffer optimization to preserve weak or transient interactions

  • Chemical crosslinking to capture transient interactions before cell lysis

• Proximity labeling techniques:

  • BioID or APEX2 fusion constructs with PAU15 to identify proximal proteins

  • MS analysis of labeled proteins to build interaction networks

• Fluorescence microscopy approaches:

  • Fluorescence colocalization with suspected interaction partners

  • FRET analysis to confirm direct interactions in vivo

  • Live-cell imaging to track dynamic interactions during stress response

• Genetic interaction mapping:

  • Synthetic genetic array analysis with PAU15 deletion strains

  • Correlation of genetic and physical interaction networks

This comprehensive approach to protein interaction analysis parallels methods used in studying other stress-responsive proteins, such as the examination of PAUF interactions in cancer contexts, where monoclonal antibodies have been instrumental in elucidating molecular mechanisms .

What methodological approaches are most effective for studying PAU15 expression in different yeast growth phases?

To effectively study PAU15 expression patterns across different growth phases and conditions:

• Growth phase-specific sampling strategy:

  • Early exponential phase (OD600 ~0.2-0.4)

  • Mid-exponential phase (OD600 ~0.6-0.8)

  • Late exponential/early diauxic shift (OD600 ~1.0-1.5)

  • Post-diauxic shift (OD600 ~2.0-3.0)

  • Early stationary phase (24-48 hours)

  • Late stationary phase (3-7 days)

• Quantification methodologies:

  • Western blotting with internal loading controls

  • RT-qPCR for transcript-level analysis

  • Flow cytometry for population-level analysis if using tagged constructs

• Data normalization approaches:

  • Normalization to constitutively expressed proteins (e.g., actin, GAPDH)

  • Consideration of total protein methods (Ponceau staining)

  • Use of spike-in controls for absolute quantification

• Integration with global expression datasets:

  • Correlation with transcriptomic data

  • Comparison with proteomics datasets

  • Analysis of PTM changes across growth phases

This detailed approach to expression analysis mirrors methodologies used in studying expression patterns of other proteins, such as the examination of PED expression in tumor versus non-tumoral tissues, where careful quantification and normalization strategies were essential for meaningful comparisons .

How might PAU15 antibody be adapted for high-throughput screening applications?

Adapting PAU15 antibody for high-throughput screening represents an advanced research application:

• Assay miniaturization strategies:

  • Adaptation to 384 or 1536-well formats

  • Optimization of minimum required cell numbers

  • Development of homogeneous (no-wash) detection formats

• Automation-compatible protocols:

  • Robust liquid handling-compatible procedures

  • Minimization of wash steps and incubation times

  • Stable detection reagents with extended bench stability

• Readout technologies:

  • Development of ELISA-based quantification systems

  • Adaptation to automated imaging platforms

  • Integration with bead-based multiplexing approaches

• Validation requirements:

  • Determination of Z' factor across multiple conditions

  • Establishment of appropriate positive and negative controls

  • Assessment of day-to-day and plate-to-plate variability

This forward-looking approach builds upon methodologies developed for other antibody-based research applications, similar to how monoclonal antibodies have been adapted for various research and clinical applications, as seen with the development of therapeutic antibodies like PBP1510 .

What considerations are important when developing functional assays using PAU15 antibody?

Development of functional assays based on PAU15 antibody requires careful consideration of:

• Neutralization potential assessment:

  • Determine if antibody binding affects PAU15 function

  • Design assays to measure functional consequences of antibody binding

• Intracellular delivery strategies (if applicable):

  • Protein transfection methods (cell-penetrating peptides, lipid-based carriers)

  • Expression of intrabodies through genetic engineering

  • Microinjection approaches for single-cell studies

• Readout selection for functional impact:

  • Growth rate measurements under stress conditions

  • Cell wall integrity assays

  • Metabolic activity measurements

  • Stress response gene expression profiling

• Controls for antibody-mediated effects:

  • Isotype controls to rule out non-specific effects

  • Fab fragments to distinguish between binding and crosslinking effects

  • Correlation with genetic knockout phenotypes

This systematic approach to functional assay development draws from principles applied to other antibody-based functional studies, including those examining the functional consequences of antibody binding to targets like PAUF, where neutralization of target function by antibodies has been demonstrated to affect cellular processes such as migration and invasion .